Last Price$126.3(1.2%)
Market Cap$36.5B
LTM Cash & Cash Equivalents
$1,467.0M
YoY Growth
-16.1%
3Y CAGR
+9.6%
5Y CAGR
+3.7%
Stock quality & Intrinsic value
7/10
17.9% overvalued
Agilent Technologies, Inc. Cash & Cash Equivalents
Annual
Quarterly
LTM
Crunching data... Almost there!
| Oct'05 | Oct'06 | Oct'07 | Oct'08 | Oct'09 | Oct'10 | Oct'11 | Oct'12 | Oct'13 | Oct'14 | Oct'15 | Oct'16 | Oct'17 | Oct'18 | Oct'19 | Oct'20 | Oct'21 | Oct'22 | Oct'23 | Oct'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Cash Equivalents | $2,226.0M | $2,262.0M | $1,826.0M | $1,405.0M | $2,479.0M | $2,649.0M | $3,527.0M | $2,351.0M | $2,675.0M | $2,218.0M | $2,003.0M | $2,289.0M | $2,678.0M | $2,247.0M | $1,382.0M | $1,441.0M | $1,484.0M | $1,053.0M | $1,590.0M | $1,329.0M |
Overvalued or undervalued?
Check the intrinsic value for A
and see if it's the right time to invest.
Agilent Technologies, Inc. (A) Cash & Cash Equivalents comparison analysis
General
LTM Cash & Cash Equivalents
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Agilent Technologies, Inc.A
$1,467.0M
(16.1%)
9.6%
3.7%
Median Peer Set
$1,009.9M
(16.3%)
(3.3%)
5.1%
Thermo Fisher Scientific Inc.TMO
$4,009.0M
(50.4%)
(3.6%)
10.8%
Danaher CorporationDHR
$2,078.0M
(64.6%)
(7.0%)
(36.4%)
IQVIA Holdings Inc.IQV
$1,702.0M
23.7%
7.6%
15.3%
Laboratory Corporation of America HoldingsLH
$1,518.7M
182.9%
1.0%
35.1%
Illumina, Inc.ILMN
$1,127.0M
7.5%
(2.9%)
(11.2%)
Natera, Inc.NTRA
$892.8M
33.5%
111.0%
76.9%
Quest Diagnostics IncorporatedDGX
$549.0M
(20.0%)
(14.3%)
(14.4%)
Waters CorporationWAT
$325.4M
(17.6%)
(13.4%)
(0.6%)
IDEXX Laboratories, Inc.IDXX
$288.3M
(36.5%)
25.9%
26.1%
Mettler-Toledo International Inc.MTD
$59.4M
(15.0%)
(15.6%)
(22.2%)
A key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Oct'05 | Oct'06 | Oct'07 | Oct'08 | Oct'09 | Oct'10 | Oct'11 | Oct'12 | Oct'13 | Oct'14 | Oct'15 | Oct'16 | Oct'17 | Oct'18 | Oct'19 | Oct'20 | Oct'21 | Oct'22 | Oct'23 | Oct'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 5,139.0 (28.4%) | 4,973.0 (3.2%) | 5,420.0 9.0% | 5,774.0 6.5% | 4,481.0 (22.4%) | 5,444.0 21.5% | 6,615.0 21.5% | 6,858.0 3.7% | 6,782.0 (1.1%) | 6,981.0 2.9% | 4,038.0 (42.2%) | 4,202.0 4.1% | 4,472.0 6.4% | 4,914.0 9.9% | 5,163.0 5.1% | 5,339.0 3.4% | 6,319.0 18.4% | 6,848.0 8.4% | 6,833.0 (0.2%) | 6,510.0 (4.7%) |
| Cost of Goods Sold (COGS) | 2,617.0 | 2,315.0 | 2,451.0 | 2,578.0 | 2,189.0 | 2,514.0 | 3,086.0 | 3,254.0 | 3,247.0 | 3,388.0 | 1,997.0 | 2,005.0 | 2,063.0 | 2,227.0 | 2,358.0 | 2,502.0 | 2,912.0 | 3,126.0 | 3,368.0 | 2,975.0 |
% margin | 2,522.0 49.1% | 2,658.0 53.4% | 2,969.0 54.8% | 3,196.0 55.4% | 2,292.0 51.1% | 2,930.0 53.8% | 3,529.0 53.3% | 3,604.0 52.6% | 3,535.0 52.1% | 3,593.0 51.5% | 2,041.0 50.5% | 2,197.0 52.3% | 2,409.0 53.9% | 2,687.0 54.7% | 2,805.0 54.3% | 2,837.0 53.1% | 3,407.0 53.9% | 3,722.0 54.4% | 3,465.0 50.7% | 3,535.0 54.3% |
| Operating Expenses | 2,341.0 | 2,194.0 | 2,385.0 | 2,401.0 | 2,245.0 | 2,364.0 | 2,458.0 | 2,485.0 | 2,584.0 | 2,762.0 | 1,519.0 | 1,582.0 | 1,568.0 | 1,759.0 | 1,864.0 | 1,991.0 | 2,060.0 | 2,104.0 | 2,115.0 | 2,047.0 |
| Research & Development Expenses (R&D) | 738.0 | 655.0 | 685.0 | 704.0 | 642.0 | 612.0 | 649.0 | 668.0 | 704.0 | 719.0 | 330.0 | 329.0 | 339.0 | 385.0 | 404.0 | 495.0 | 441.0 | 467.0 | 481.0 | 479.0 |
| Selling, General & Administrative Expenses (SG&A) | 1,603.0 | 1,660.0 | 1,700.0 | 1,697.0 | 1,603.0 | 1,752.0 | 1,809.0 | 1,817.0 | 1,880.0 | 2,043.0 | 1,189.0 | 1,253.0 | 1,229.0 | 1,374.0 | 1,460.0 | 1,496.0 | 1,619.0 | 1,637.0 | 1,634.0 | 1,568.0 |
% margin | 181.0 3.5% | 464.0 9.3% | 584.0 10.8% | 795.0 13.8% | 47.0 1.0% | 566.0 10.4% | 1,071.0 16.2% | 1,119.0 16.3% | 951.0 14.0% | 831.0 11.9% | 522.0 12.9% | 615.0 14.6% | 841.0 18.8% | 928.0 18.9% | 941.0 18.2% | 846.0 15.8% | 1,347.0 21.3% | 1,618.0 23.6% | 1,350.0 19.8% | 1,488.0 22.9% |
| Interest Income | 0.0 | 0.0 | 172.0 | 113.0 | 29.0 | 20.0 | 14.0 | 9.0 | 7.0 | 9.0 | 7.0 | 11.0 | 22.0 | 38.0 | 36.0 | 8.0 | 2.0 | 9.0 | 51.0 | 80.0 |
| Interest Expense | 0.0 | 0.0 | 91.0 | 123.0 | 88.0 | 96.0 | 86.0 | 101.0 | 107.0 | 113.0 | 66.0 | 72.0 | 79.0 | 75.0 | 74.0 | 78.0 | 81.0 | 84.0 | 95.0 | 96.0 |
| Pre-tax Income | 254.0 | 627.0 | 670.0 | 815.0 | 7.0 | 692.0 | 1,032.0 | 1,043.0 | 859.0 | 646.0 | 480.0 | 544.0 | 803.0 | 946.0 | 919.0 | 842.0 | 1,360.0 | 1,504.0 | 1,339.0 | 1,521.0 |
% effective tax rate | 155.0 61.0% | 91.0 14.5% | 32.0 4.8% | 122.0 15.0% | 38.0 542.9% | 68.0 9.8% | 20.0 1.9% | (110.0) (10.5%) | 135.0 15.7% | 149.0 23.1% | 45.0 9.4% | 84.0 15.4% | 119.0 14.8% | 630.0 66.6% | (152.0) (16.5%) | 123.0 14.6% | 150.0 11.0% | 250.0 16.6% | 99.0 7.4% | 232.0 15.3% |
% margin | 327.0 6.4% | 3,307.0 66.5% | 638.0 11.8% | 693.0 12.0% | (31.0) (0.7%) | 624.0 11.5% | 1,012.0 15.3% | 1,153.0 16.8% | 724.0 10.7% | 497.0 7.1% | 398.0 9.9% | 460.0 10.9% | 684.0 15.3% | 316.0 6.4% | 1,071.0 20.7% | 719.0 13.5% | 1,210.0 19.1% | 1,254.0 18.3% | 1,240.0 18.1% | 1,289.0 19.8% |
| EPS | 0.66 | 7.67 | 1.62 | 1.91 | (0.09) | 1.80 | 2.92 | 3.31 | 2.12 | 1.49 | 1.20 | 1.41 | 2.12 | 0.98 | 3.41 | 2.33 | 3.98 | 4.19 | 4.22 | 4.43 |
| Diluted EPS | 0.65 | 7.50 | 1.57 | 1.87 | (0.09) | 1.77 | 2.85 | 3.27 | 2.10 | 1.47 | 1.19 | 1.40 | 2.10 | 0.97 | 3.37 | 2.30 | 3.94 | 4.18 | 4.19 | 4.43 |
% margin | 396.0 7.7% | 634.0 12.7% | 775.0 14.3% | 1,139.0 19.7% | 257.0 5.7% | 788.0 14.5% | 1,395.0 21.1% | 1,445.0 21.1% | 758.0 11.2% | 648.0 9.3% | 778.0 19.3% | 863.0 20.5% | 1,096.0 24.5% | 1,181.0 24.0% | 1,281.0 24.8% | 1,353.0 25.3% | 1,725.0 27.3% | 1,994.0 29.1% | 1,703.0 24.9% | 1,488.0 22.9% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Agilent Technologies, Inc.'s Cash & Cash Equivalents?
As of today, Agilent Technologies, Inc.'s last 12-month Cash & Cash Equivalents is $1,467.0M, based on the financial report for Jan 31, 2025 (Q1’2025).
2) What is Agilent Technologies, Inc.'s Cash & Cash Equivalents growth rate?
Over the last year, Agilent Technologies, Inc.'s Cash & Cash Equivalents growth was (16.1%). The average annual Cash & Cash Equivalents growth rates for Agilent Technologies, Inc. have been 0.9% over the past three years, 3.7% over the past five years.
3) Is Agilent Technologies, Inc.'s Cash & Cash Equivalents growth rate Good?
Over the last year, Agilent Technologies, Inc.'s Cash & Cash Equivalents growth was (16.1%), which is lower than industry growth of (0.1%). It indicates that Agilent Technologies, Inc.'s Cash & Cash Equivalents growth is Bad.